Macro Dragon: Putting Compass on the Map... Mycelium, Magic Mushrooms + Psychedelics for Medicine & Treatment

Macro Dragon: Putting Compass on the Map... Mycelium, Magic Mushrooms + Psychedelics for Medicine & Treatment

Macro 2 minutes to read
Kay Van-Petersen

Global Macro Strategist

Summary:  Macro Dragon = Cross-Asset Daily Views that could cover anything from tactical positioning, to long-term thematic investments, key events & inflection points in the markets, all with the objective of consistent wealth creation overtime.


(These are solely the views & opinions of KVP, & do not constitute any trade or investment recommendations. By the time you synthesize this, things may have changed.)

Macro Dragon: Putting Compass on the Map... Mycelium, Magic Mushrooms + Psychedelics for Medicine & Treatment 

 

Top of Mind…

  • As a refresher INIL, is the moniker Invest Now, Investigate Later – its supposed to be attributed to the leviathan, Soros (like all legends, you don’t need the full name!). The idea is that often you come across something that has the makings/sound/look of a truly compelling investment… yet for whatever reason, you may not currently have the time & bandwidth to look deeply into it…

  • So you put an INIL on, which is dipping your toe into it. If your initially wrong, that’s ok.. you dipped a toe in, cost is minimized. Yet once it’s in one’s portfolio, one greatly magnifies the probability of doing the detailed work to really decide whether its likely a dud or falls into the “too hard bucket” that needs to be folded, or is in the “buy it like a piggie” bucket, & hence one needs to massively upgrade the exposure.

  • We’ve discussed the Cannabis revolution c. 2yrs back [still very much in motion & a multi-decade theme, cannabinoid, edibles, drinks, globally deregulation & education, greater tax for governments, lower crime, medicine over drug, etc], yet KVP has been on the look-out for the investment theme of psychedelics for a long time – especially in the potential treatment of depression, likely a multi-trillion problem globally.

  • A lot of people don’t realise that the modern day healthcare & pharmaceutical business model is built around trimming the weeds of diseases & ailments, but not in uprooting the problem – simply due to profitability. Why give a permanent treatment for $100,000 when one can charge $25,000 a year for “treating” the subjects for the rest of they life? The pharma drug business is the ultimate bond coupon business…

  • Hence when Compass Pathways [CMPS] – backed by the likes of Peter Thiel, Mike Novogratz, Founders Fund & Christian Angermayer (authority bias alert!) – went public last wk, the Dragon took note.

  • Like most IPOs of late [Snowflake & Unity], it was priced better than expected at $17 post a range of $14 - $16m, then popped +71% on its first day to $29.

  • Taking the company to a $986m mkt cap, after which it had raised close to $130m – most of which has been earmarked for clinical trials & research. Just to give context on mkt size, goliath Pfizer is $204bn in mkt cap, so yes similar to BYND, TSLA… CMPS likely will always have a potential take-over optionality attached to it.
  • Whilst psychedelics have a tainted narrative (think Nixon & Reagan political drug propaganda that also coincided with the hippie era) & most seen as recreational drugs, there are medicinal natural uses going back centuries & spread out across different cultures around the globe (think mushrooms, DMT).
  • For a period of close to 50-60 years there has been a vacuum & black hole of research in the space, that is now rapidly trying to catch up on time. For some clinical depressive patients who have been on heavy medication for decades, they have called some of these treatments tens years of therapy in one session.
  • So whilst KVP still needs to dig much deeper into Compass Pathway, in regards to the theme, of psychedelics becoming part of mainstream medicines & treatment over the next five to fifteen years, he is a mega-bull.
  • Goes without saying, like any industry that is in the pioneering stage, there will be a lot of risk, noise, charlatans & vested interests both for & against it.

-

On The Radar Today…

  • JP: Still out on public hols, will be back in on Weds

  • US: Existing Home Sales, Richmond Mfg. Index, Powell Testifies @ 22:30

  • UK: Public Sector Net Borrowing, BoE Governor Bailey @ 15:30 SGT

  • EZ: Consumer Confidence

  • CH: CB leading index

    Note Wed will be flash PMIs across the board

-

Dragon's Must Reads

  • For the equity & equity tech fans - Eleanor Creagh highlighting Ant Group to join IPO rush

    Ant Group, China's dominant mobile payments firm, are set to dominate the listed fintech space with their upcoming, humongous, record setting IPO. The Chinese fintech company founded by former Alibaba Group Holding (BABA) Executive Chairman Jack Ma operates the e-commerce giant's Alipay payment service and could be the largest IPO ever when it dual-lists on the Hong Kong and Shanghai's Nasdaq-style STAR Market exchanges later this year..

  • John Hardy dropping a roadmap US Election Primer: The Final Sprint to November 3rd

    We sort through important dates in this final sprint phase of the absurdly long US presidential election cycle. Historically, we have seen significant shifts in the polling in the final weeks leading up to the election. As well, we consider factors that can change the odds between now and Election Day on November 3rd.

  • Saxo’s US Election Cheat Sheet Which cuts into the three potential pathways into the elections, probabilities around them, as well as short & long-term positions across equities, bonds, commodities & currencies.

-

Start-to-End = Gratitude + Integrity + Vision + Tenacity  | Process > Outcome | Sizing > Idea.

This is the way 

KVP

Quarterly Outlook

01 /

  • Equity outlook: The high cost of global fragmentation for US portfolios

    Quarterly Outlook

    Equity outlook: The high cost of global fragmentation for US portfolios

    Charu Chanana

    Chief Investment Strategist

  • Commodity Outlook: Commodities rally despite global uncertainty

    Quarterly Outlook

    Commodity Outlook: Commodities rally despite global uncertainty

    Ole Hansen

    Head of Commodity Strategy

  • Upending the global order at blinding speed

    Quarterly Outlook

    Upending the global order at blinding speed

    John J. Hardy

    Global Head of Macro Strategy

    We are witnessing a once-in-a-lifetime shredding of the global order. As the new order takes shape, ...
  • Asset allocation outlook: From Magnificent 7 to Magnificent 2,645—diversification matters, now more than ever

    Quarterly Outlook

    Asset allocation outlook: From Magnificent 7 to Magnificent 2,645—diversification matters, now more than ever

    Jacob Falkencrone

    Global Head of Investment Strategy

  • Macro outlook: Trump 2.0: Can the US have its cake and eat it, too?

    Quarterly Outlook

    Macro outlook: Trump 2.0: Can the US have its cake and eat it, too?

    John J. Hardy

    Global Head of Macro Strategy

  • Equity Outlook: The ride just got rougher

    Quarterly Outlook

    Equity Outlook: The ride just got rougher

    Charu Chanana

    Chief Investment Strategist

  • China Outlook: The choice between retaliation or de-escalation

    Quarterly Outlook

    China Outlook: The choice between retaliation or de-escalation

    Charu Chanana

    Chief Investment Strategist

  • Commodity Outlook: A bumpy road ahead calls for diversification

    Quarterly Outlook

    Commodity Outlook: A bumpy road ahead calls for diversification

    Ole Hansen

    Head of Commodity Strategy

  • FX outlook: Tariffs drive USD strength, until...?

    Quarterly Outlook

    FX outlook: Tariffs drive USD strength, until...?

    John J. Hardy

    Global Head of Macro Strategy

  • Fixed Income Outlook: Bonds Hit Reset. A New Equilibrium Emerges

    Quarterly Outlook

    Fixed Income Outlook: Bonds Hit Reset. A New Equilibrium Emerges

    Althea Spinozzi

    Head of Fixed Income Strategy

None of the information provided on this website constitutes an offer, solicitation, or endorsement to buy or sell any financial instrument, nor is it financial, investment, or trading advice. Saxo Capital Markets UK Ltd. (Saxo) and the Saxo Bank Group provides execution-only services, with all trades and investments based on self-directed decisions. Analysis, research, and educational content is for informational purposes only and should not be considered advice nor a recommendation. Access and use of this website is subject to: (i) the Terms of Use; (ii) the full Disclaimer; (iii) the Risk Warning; and (iv) any other notice or terms applying to Saxo’s news and research.

Saxo’s content may reflect the personal views of the author, which are subject to change without notice. Mentions of specific financial products are for illustrative purposes only and may serve to clarify financial literacy topics. Content classified as investment research is marketing material and does not meet legal requirements for independent research.

Before making any investment decisions, you should assess your own financial situation, needs, and objectives, and consider seeking independent professional advice. Saxo does not guarantee the accuracy or completeness of any information provided and assumes no liability for any errors, omissions, losses, or damages resulting from the use of this information.

Please refer to our full disclaimer for more details.

Saxo
40 Bank Street, 26th floor
E14 5DA
London
United Kingdom

Contact Saxo

Select region

United Kingdom
United Kingdom

Trade Responsibly
All trading carries risk. To help you understand the risks involved we have put together a series of Key Information Documents (KIDs) highlighting the risks and rewards related to each product. Read more
Additional Key Information Documents are available in our trading platform.

Saxo is a registered Trading Name of Saxo Capital Markets UK Ltd (‘Saxo’). Saxo is authorised and regulated by the Financial Conduct Authority, Firm Reference Number 551422. Registered address: 26th Floor, 40 Bank Street, Canary Wharf, London E14 5DA. Company number 7413871. Registered in England & Wales.

This website, including the information and materials contained in it, are not directed at, or intended for distribution to or use by, any person or entity who is a citizen or resident of or located in the United States, Belgium or any other jurisdiction where such distribution, publication, availability or use would be contrary to applicable law or regulation.

It is important that you understand that with investments, your capital is at risk. Past performance is not a guide to future performance. It is your responsibility to ensure that you make an informed decision about whether or not to invest with us. If you are still unsure if investing is right for you, please seek independent advice. Saxo assumes no liability for any loss sustained from trading in accordance with a recommendation.

Apple, iPad and iPhone are trademarks of Apple Inc., registered in the U.S. and other countries. App Store is a service mark of Apple Inc. Android is a trademark of Google Inc.

©   since 1992